GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veritas In Silico Inc (TSE:130A) » Definitions » Total Current Liabilities

Veritas In Silico (TSE:130A) Total Current Liabilities : 円37.3 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Veritas In Silico Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Veritas In Silico's total current liabilities for the quarter that ended in Jun. 2024 was 円37.3

Veritas In Silico Total Current Liabilities Historical Data

The historical data trend for Veritas In Silico's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veritas In Silico Total Current Liabilities Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23
Total Current Liabilities
70.82 55.99 79.89

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24
Total Current Liabilities Get a 7-Day Free Trial 55.99 101.14 79.89 58.05 37.27

Veritas In Silico Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Veritas In Silico's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=27.314+0
+Other Current Liabilities+Current Deferred Liabilities
=52.578+0
=79.9

Veritas In Silico's Total Current Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=19.833+0
+Other Current Liabilities+Current Deferred Liabilities
=17.438+0
=37.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Veritas In Silico Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Veritas In Silico's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Veritas In Silico Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veritas In Silico Inc (TSE:130A) » Definitions » Total Current Liabilities
Comparable Companies
Traded in Other Exchanges
N/A
Address
1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Website
https://www.veritasinsilico.com
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.

Veritas In Silico Headlines

No Headlines